Stem Cell Sciences Wins EU Funding To Use Stem Cells For Drug Discovery
Stem Cell Sciences plc (SCS; AIM:STEM, ASX: STC) announces that it is to lead an EU funded, multinational novel drug screening collaboration using stem cells. The project, named “NEUROscreen”, will use Stem Cell Sciences’ proprietary neural stem (NS) cell technology and has received a contribution from the EU’s 6th Framework Programme for Research and Technical Development (FP6). The EU’s contribution to the NEUROscreen project is worth €2.
